Expert Interview
Discussing the potential of Corcept Therapeutics relacorilant plus nab-paclitaxelpivotal and the results from the Phase 3 ROSELLA trial in patients with platinum-resistant ovarian cancer.
Ticker(s): CORTInstitution: Stanford
- Mary Lake Polan Professor and Director of the Division of Gynecologic Oncology
- Treats ~110 patients with endometrial cancer every year
- Research interest in Gene Therapy, genetically modified tumor cell vaccines, gene transfer systems, CAR-T therapies, and ADCs.
Please describe your clinical practice. How many patients with ovarian cancer? What percent of ovarian cancers become platinum-resistant and how do you measure benefit when proceeding with treatment?
Added By: sara_adminCould you please tell us more about the mechanisms of platinum resistance, and the treatment options patients with PROC have? And what is platinum refractory disease?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of relacorilant plus nab-paclitaxelpivotal, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
